Submit Manuscript  

Article Details


VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy

[ Vol. 17 , Issue. 9 ]

Author(s):

B. Lan, S. Chai, P. Wang* and K. Wang*   Pages 608 - 618 ( 11 )

Abstract:


VCP/p97/Cdc48, a member of the ATPases associated with diverse cellular activities (AAA) family, is necessary for the endoplasmic-reticulum-associated protein degradation (ERAD) pathway to maintain protein homeostasis. Overwhelming proteotoxic stress drove cancer cells to enhance VCP/p97/Cdc48-associated ERAD to maintain protein homeostasis for survival, demonstrating that VCP/p97/Cdc48 expression was positively correlated with cancer prognosis. More studies revealed that targeting VCP/p97/Cdc48 could be a potential target in cancer therapy. CB-5083, a novel inhibitor of VCP/p97/Cdc48, is in clinical trials as the first VCP/p97/Cdc48- inhibiting drug for cancer therapy. Here, we discuss the relationship between VCP/p97/Cdc48, ERAD, protein homeostasis and cancer therapy.

Keywords:

VCP/p97/Cdc48, protein homeostasis, ERAD, cancer therapy, ER stress, CB-5083.

Affiliation:

Department of Respiratory Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Department of Oncology, Ningbo First Hospital, Ningbo, Department of Respiratory Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Department of Respiratory Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou



Read Full-Text article